Aradigm
PrivateLast Round
Series A
Dec 9, 2025
Est. Valuation
$25M
Total Funding Raised
$30M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aradigm is a healthcare technology company that provides a benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aradigm Comparables
Compare Aradigm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Real Endpoints | 33% | |
| Audaire Health | 32% | |
| Quantile Health | 30% | |
Aradigm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 9, 2025 |
Aradigm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Seed |
| Frist Cressey Ventures | Series A |
| Morgan Health | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
CEO interviewed at the Asembia ASX26 Summit in Las Vegas.
Aradigm Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aradigm's valuation, stock price, and market status.